Who are Deep neuromuscular block's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rocuronium + sugammadex, Vecuronium + Atracurium, Rocuronium or Vecuronium, NMBA - cisatracurium, Neuromuscular Blocking Agents, Rocuronium dosing.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/deep-neuromuscular-block.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Deep neuromuscular block — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Deep neuromuscular block (Deep neuromuscular block) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Anesthesiology.

marketed Nicotinic acetylcholine receptor at the neuromuscular junction Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Deep neuromuscular block (Deep neuromuscular block) — University of Medicine and Pharmacy at Ho Chi Minh City. Deep neuromuscular block refers to a state of profound neuromuscular blockade achieved through administration of neuromuscular blocking agents that inhibit acetylcholine at the neuromuscular junction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Deep neuromuscular block TARGET	Deep neuromuscular block	University of Medicine and Pharmacy at Ho Chi Minh City	marketed		Nicotinic acetylcholine receptor at the neuromuscular junction
Rocuronium + sugammadex	Rocuronium + sugammadex	Brno University Hospital	marketed	Neuromuscular blocking agent (rocuronium) + selective relaxant binding agent (sugammadex)	Nicotinic acetylcholine receptor at the neuromuscular junction (rocuronium); rocuronium molecule itself (sugammadex)
Vecuronium + Atracurium	Vecuronium + Atracurium	Sir Ganga Ram Hospital	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction
Rocuronium or Vecuronium	Rocuronium or Vecuronium	Merck Sharp & Dohme LLC	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction
NMBA - cisatracurium	NMBA - cisatracurium	CHU de Reims	marketed	Non-depolarizing neuromuscular blocking agent (NMBA)	Nicotinic acetylcholine receptor at the neuromuscular junction
Neuromuscular Blocking Agents	Neuromuscular Blocking Agents	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	Neuromuscular blocking agent	Nicotinic acetylcholine receptor at the neuromuscular junction
Rocuronium dosing	Rocuronium dosing	Clare Hayes-Bradley	marketed	Neuromuscular blocking agent (non-depolarizing)	Nicotinic acetylcholine receptor at the neuromuscular junction

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Deep neuromuscular block — Competitive Intelligence Brief. https://druglandscape.com/ci/deep-neuromuscular-block. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing